HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Mark Marino

Chief Medical Officer

Dr Marino leads the Company’s global clinical development, regulatory and medical monitoring activities. Dr Marino brings deep experience to the Company, having held senior level clinical development/leadership & CMO positions at top tier pharmaceutical companies, including Daiichi-Sankyo, Hoffman-La Roche AG, and Novartis Pharmaceuticals Corp.  In his previous roles, Dr Marino headed teams in oncology, cardiology, endocrinology and rare-diseases where he was responsible for clinical development through to commercialization and life cycle management.  He also successfully engaged key stakeholders including the scientific community, scientific boards, advocacy groups and key opinion leaders.  Prior to his move into the pharmaceutical industry, Dr Marino spent 7 years with the US Military’s Walter Reed Army Institute of Research, the Walter Reed Army Medical Center and the Uniformed Services University of the Health Sciences.

Dr Marino holds a Medical Doctor degree from the Albert Einstein College of Medicine and a Bachelor of Science in Chemistry from the United States Military Academy.


© Imugene 2018. All rights reserved. ABN 99 009 179 551